A Crossover Study to Evaluate the Safety, Tolerability and Efficacy of XPF-002 in Subjects With Postherpetic Neuralgia (PHN)

NCT01195636 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Postherpetic Neuralgia

Interventions

DRUG: XPF-002
DRUG: Placebo

Sponsor

Xenon Pharmaceuticals Inc.